BRIACELL THERAPEUTICS CORP.: 10-Q filed 2023-06-14
What BRIACELL THERAPEUTICS CORP. reported in its quarterly report filed 2023-06-14 (fiscal Q3 2023): 27 published measures, 79 facts as tagged in accession 0001493152-23-021287.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2023-06-14
- Fiscal period
- fiscal Q3 2023
- Accession
- 0001493152-23-021287 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BRIACELL THERAPEUTICS CORP. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-04-30 | 29,721,868 | USD | |
| At 2022-07-31 | 42,577,041 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-04-30 | -5,892,342 | USD | |
| At 2023-01-31 | -1,280,586 | USD | |
| At 2022-07-31 | 10,328,932 | USD | |
| At 2022-04-30 | 9,958,452 | USD | |
| At 2022-01-31 | 16,425,698 | USD | |
| At 2021-07-31 | 27,671,721 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-04-30 | 28,170,099 | USD | |
| At 2022-07-31 | 41,041,652 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-02-01 to 2023-04-30 | -4,895,436 | USD | 89 |
| 2022-08-01 to 2023-04-30 | -17,883,739 | USD | 273 |
| 2022-02-01 to 2022-04-30 | -10,015,573 | USD | 89 |
| 2021-08-01 to 2022-04-30 | -26,388,551 | USD | 273 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-08-01 to 2023-04-30 | -12,825,853 | USD | 273 |
| 2021-08-01 to 2022-04-30 | -9,158,647 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-08-01 to 2023-04-30 | -45,700 | USD | 273 |
| 2021-08-01 to 2022-04-30 | -3,582,874 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-04-30 | -78,233,576 | USD | |
| At 2022-07-31 | -60,349,837 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-02-01 to 2023-04-30 | 15,518,072 | shares | 89 |
| 2022-08-01 to 2023-04-30 | 15,518,036 | shares | 273 |
| 2022-02-01 to 2022-04-30 | 15,358,947 | shares | 89 |
| 2021-08-01 to 2022-04-30 | 15,486,028 | shares | 273 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-02-01 to 2023-04-30 | 15,518,072 | shares | 89 |
| 2022-08-01 to 2023-04-30 | 15,518,036 | shares | 273 |
| 2022-02-01 to 2022-04-30 | 15,358,947 | shares | 89 |
| 2021-08-01 to 2022-04-30 | 15,486,028 | shares | 273 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-02-01 to 2023-04-30 | -0.32 | USD/shares | 89 |
| 2022-08-01 to 2023-04-30 | -1.15 | USD/shares | 273 |
| 2022-02-01 to 2022-04-30 | -0.65 | USD/shares | 89 |
| 2021-08-01 to 2022-04-30 | -1.7 | USD/shares | 273 |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-02-01 to 2023-04-30 | 281,189 | USD | 89 |
| 2022-08-01 to 2023-04-30 | 1,659,974 | USD | 273 |
| 2022-02-01 to 2022-04-30 | 863,627 | USD | 89 |
| 2021-08-01 to 2022-04-30 | 2,196,637 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-02-01 to 2023-04-30 | -5,677,029 | USD | 89 |
| 2022-08-01 to 2023-04-30 | -15,566,503 | USD | 273 |
| 2022-02-01 to 2022-04-30 | -4,123,260 | USD | 89 |
| 2021-08-01 to 2022-04-30 | -10,054,878 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-04-30 | 29,502,980 | USD | |
| At 2022-07-31 | 42,346,700 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-08-01 to 2022-04-30 | 979 | USD | 273 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-04-30 | 1,383,094 | USD | |
| At 2022-07-31 | 941,087 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-04-30 | 218,886 | USD | |
| At 2022-07-31 | 230,339 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-04-30 | 14,896 | USD | |
| At 2022-07-31 | 24,103 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-02-01 to 2023-04-30 | 5,677,029 | USD | 89 |
| 2022-08-01 to 2023-04-30 | 15,566,503 | USD | 273 |
| 2022-02-01 to 2022-04-30 | 4,123,260 | USD | 89 |
| 2021-08-01 to 2022-04-30 | 10,054,878 | USD | 273 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-02-01 to 2023-04-30 | 3,860,568 | USD | 89 |
| 2022-08-01 to 2023-04-30 | 10,169,140 | USD | 273 |
| 2022-02-01 to 2022-04-30 | 2,268,805 | USD | 89 |
| 2021-08-01 to 2022-04-30 | 4,852,620 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-04-30 | 15,518,318 | shares | |
| At 2022-07-31 | 15,269,853 | shares |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-04-30 | -138,684 | USD | |
| At 2022-07-31 | -138,684 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-02-01 to 2023-04-30 | -4,895,436 | USD | 89 |
| 2022-08-01 to 2023-04-30 | -17,883,739 | USD | 273 |
| 2022-02-01 to 2022-04-30 | -10,015,573 | USD | 89 |
| 2021-08-01 to 2022-04-30 | -26,388,551 | USD | 273 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-02-01 to 2023-04-30 | 1,816,461 | USD | 89 |
| 2022-08-01 to 2023-04-30 | 5,397,363 | USD | 273 |
| 2022-02-01 to 2022-04-30 | 1,854,455 | USD | 89 |
| 2021-08-01 to 2022-04-30 | 5,202,258 | USD | 273 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-08-01 to 2023-04-30 | 11,453 | USD | 273 |
| 2021-08-01 to 2022-04-30 | 11,453 | USD | 273 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-02-01 to 2023-04-30 | 781,593 | USD | 89 |
| 2022-08-01 to 2023-04-30 | -2,317,236 | USD | 273 |
| 2022-02-01 to 2022-04-30 | -5,892,313 | USD | 89 |
| 2021-08-01 to 2022-04-30 | -16,333,673 | USD | 273 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-08-01 to 2023-04-30 | -9,207 | USD | 273 |
| 2021-08-01 to 2022-04-30 | 1,958 | USD | 273 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-08-01 to 2023-04-30 | 531,972 | USD | 273 |
| 2021-08-01 to 2022-04-30 | 6,945 | USD | 273 |
Inspect the source
- Entity
- BRIACELL THERAPEUTICS CORP. / CIK 0001610820
- Captured
- 2026-09-20T09:26:46.138Z
- SEC response SHA-256
9b120e952e46202c087d84b15420884d11dabee9617ee209952acee5219f65e1
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001610820.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))